Business Case Studies, Strategy Case Study, Mergers, Acquisitions, Alliances and Synergies

print page
Tell A Friend
Bookmark

Mergers, Acquisitions, Alliances and Synergies Case Study

IBS CDC IBS CDC IBS CDC IBS CDC RSS Feed
Case Title:

Ranbaxy’s Sell-off to Daiichi – Rise of a New Business Model in Global Pharma?

Publication Month and Year :  Jan 2009

Authors: Faraz Shafiuddin, Girija. P

Industry: Pharmaceutical Industry

Region: India

Case Code: MAA0184

Teaching Note: Available

Structured Assignment: Available


OR





Abstract:
The fast-growing emerging markets have gained considerable significance with the Big Pharma losing out on their global market share. India, the growing hub of R&D in global pharma, is fast catching up as an alternative for sustaining competitive advantage. In 2008, the sell-out decision by Ranbaxy, the largest pharmaceutical in India, is seen as a sign of the changing dimensions of faster consolidation in global pharma. Ranbaxy, a generic firm, sold its majority stake to Daiichi-Sankyo, a top Japanese innovation company, setting a new trend. The cross-border acquisition is perceived as a growing tendency of companies to focus on future sustainability than on mere profit margins. Both companies are complimenting each other, with Ranbaxy foregoing national interests for stronger global competitiveness. This hybrid model has triggered a new phase of M&A in global pharma, as Big Pharma start desperate measures of new mutual collaborations and alliances to risk losing their market share from their generic players.

Pedagogical Objectives:

  • To examine the changing market dynamics amidst competition to traditional pharma companies from generic drug makers
  • To evaluate the value chain of pharma industry and examine the different business models that evolved
  • To analyse the growth drivers of pharma companies
  • To identify the need for a hybrid business model and analyse the effects of Ranbaxy’s sell-out to Daiichi on both the companies and the industry as a whole.

Keywords :  Ranbaxy, International Patent, Daiichi, Business Model, Pharmaceutical, Acquisition, Generic drugs, Research and development, Blockbuster drugs, clinical trials

Related Links

Useful links

Currency Exchange Rates

Case Study :
   INR 200 = USD ($)

Structured Assignment:
   INR 150 = USD ($)

Teaching Note :
   INR 400 = USD ($)
c

Ad

Contact us: IBS Case Development Centre (IBSCDC), IFHE Campus, Donthanapally, Sankarapally Road, Hyderabad-500 082, Telangana, INDIA.
Mob: +91- 9640901313,
E-mail: casehelpdesk@ibsindia.org

©2020 - 25 IBS Case Development Centre. All rights reserved. | Careers | Privacy Policy | Terms of Use | Disclosure | Site Map xml sitemap